{"id":12200,"date":"2022-11-18T13:48:55","date_gmt":"2022-11-18T13:48:55","guid":{"rendered":"https:\/\/dailytalks.org\/?p=12200"},"modified":"2022-11-18T13:48:55","modified_gmt":"2022-11-18T13:48:55","slug":"astrazeneca-imfinzi-combination-recommended-for-approval-in-eu-for-advanced-biliary-tract-cancer","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=12200","title":{"rendered":"AstraZeneca : Imfinzi Combination Recommended For Approval In EU For Advanced Biliary Tract Cancer"},"content":{"rendered":"<p>RTTNews) &#8211; AstraZeneca Plc. (AZN.L, AZN) said that its Imfinzi (durvalumab) has been recommended for marketing authorization in the European Union for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer in combination with chemotherapy &#8230;<br \/><a href=\"https:\/\/www.nasdaq.com\/articles\/astrazeneca-:-imfinzi-combination-recommended-for-approval-in-eu-for-advanced-biliary\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>RTTNews) &#8211; AstraZeneca Plc. (AZN.L, AZN) said that its Imfinzi (durvalumab) has been recommended for<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-12200","post","type-post","status-publish","format-standard","hentry","category-europe"],"featured_image_urls":{"full":"","thumbnail":"","medium":"","medium_large":"","large":"","1536x1536":"","2048x2048":"","chromenews-featured":"","chromenews-large":"","chromenews-medium":""},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=16\" rel=\"category\">Europe<\/a>","tag_info":"Europe","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/12200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12200"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/12200\/revisions"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}